Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001104659-25-105834
Chunk: 3

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 3
---

or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2) the failure to obtain approval of
the proposed transaction from STAAR’s stockholders; (3) the failure to obtain certain required regulatory approvals or the failure
to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all;
(4) risks related to disruption of management’s attention from STAAR’s ongoing business operations due to the proposed transaction;
(5) the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain
relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally;
(6) the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings
that may be instituted against STAAR related to the proposed transaction; (8) the possibility that STAAR’s stock price may decline
significantly if the proposed transaction is not consummated; and (9) other important factors set forth in the Proxy Statement under
the caption “Risk Factors” and STAAR’s Annual Report on Form 10-K for the year ended December 27, 2024 under the caption
“Risk Factors,” as any such factors may be updated from time to time in STAAR’s other filings with the SEC.

2/3

Forward-looking statements speak only as of the date they are made
and, except as may be required under applicable law, neither Alcon nor STAAR undertake any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care
with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions
like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through
innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at .

Connect with us on

| Investor                     
 Relations                    | Media                           
 Relations                       |
| Daniel Cravens, Allen Trang  | Steven